Cargando…
Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study
OBJECTIVE: This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. DESIGN: Prospective cohort study. SETTINGS: A large public university. PARTICIPANTS: This study took volunteers over 5 days and recruited 1064 adult participants. PRIMARY OUTCOME MEASURES: Sero...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401225/ https://www.ncbi.nlm.nih.gov/pubmed/37536960 http://dx.doi.org/10.1136/bmjopen-2023-072627 |
_version_ | 1785084611270803456 |
---|---|
author | Hou, Ching-Wen Williams, Stacy Taylor, Kylee Boyle, Veronica Bobbett, Bradley Kouvetakis, Joseph Nguyen, Keana McDonald, Aaron Harris, Valerie Nussle, Benjamin Scharf, Phillip Jehn, Megan L Lant, Timothy Magee, Mitchell Chung, Yunro LaBaer, Joshua Murugan, Vel |
author_facet | Hou, Ching-Wen Williams, Stacy Taylor, Kylee Boyle, Veronica Bobbett, Bradley Kouvetakis, Joseph Nguyen, Keana McDonald, Aaron Harris, Valerie Nussle, Benjamin Scharf, Phillip Jehn, Megan L Lant, Timothy Magee, Mitchell Chung, Yunro LaBaer, Joshua Murugan, Vel |
author_sort | Hou, Ching-Wen |
collection | PubMed |
description | OBJECTIVE: This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. DESIGN: Prospective cohort study. SETTINGS: A large public university. PARTICIPANTS: This study took volunteers over 5 days and recruited 1064 adult participants. PRIMARY OUTCOME MEASURES: Seroprevalence of SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. RESULTS: The seroprevalence of the antireceptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semiquantitative chemiluminescent immunoassay. The seroprevalence for antinucleocapsid was 20%. In addition, individuals with previous natural COVID-19 infection plus vaccination had higher anti-RBD antibody levels compared with those who had vaccination only or infection only. Individuals who had a breakthrough infection had the highest anti-RBD antibody levels. CONCLUSION: Accurate estimates of the cumulative incidence of SARS-CoV-2 infection can inform the development of university risk mitigation protocols such as encouraging booster shots, extending mask mandates or reverting to online classes. It could help us to have clear guidance to act at the first sign of the next surge as well, especially since there is a surge of COVID-19 subvariant infections. |
format | Online Article Text |
id | pubmed-10401225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-104012252023-08-05 Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study Hou, Ching-Wen Williams, Stacy Taylor, Kylee Boyle, Veronica Bobbett, Bradley Kouvetakis, Joseph Nguyen, Keana McDonald, Aaron Harris, Valerie Nussle, Benjamin Scharf, Phillip Jehn, Megan L Lant, Timothy Magee, Mitchell Chung, Yunro LaBaer, Joshua Murugan, Vel BMJ Open Epidemiology OBJECTIVE: This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. DESIGN: Prospective cohort study. SETTINGS: A large public university. PARTICIPANTS: This study took volunteers over 5 days and recruited 1064 adult participants. PRIMARY OUTCOME MEASURES: Seroprevalence of SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. RESULTS: The seroprevalence of the antireceptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semiquantitative chemiluminescent immunoassay. The seroprevalence for antinucleocapsid was 20%. In addition, individuals with previous natural COVID-19 infection plus vaccination had higher anti-RBD antibody levels compared with those who had vaccination only or infection only. Individuals who had a breakthrough infection had the highest anti-RBD antibody levels. CONCLUSION: Accurate estimates of the cumulative incidence of SARS-CoV-2 infection can inform the development of university risk mitigation protocols such as encouraging booster shots, extending mask mandates or reverting to online classes. It could help us to have clear guidance to act at the first sign of the next surge as well, especially since there is a surge of COVID-19 subvariant infections. BMJ Publishing Group 2023-08-03 /pmc/articles/PMC10401225/ /pubmed/37536960 http://dx.doi.org/10.1136/bmjopen-2023-072627 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Epidemiology Hou, Ching-Wen Williams, Stacy Taylor, Kylee Boyle, Veronica Bobbett, Bradley Kouvetakis, Joseph Nguyen, Keana McDonald, Aaron Harris, Valerie Nussle, Benjamin Scharf, Phillip Jehn, Megan L Lant, Timothy Magee, Mitchell Chung, Yunro LaBaer, Joshua Murugan, Vel Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study |
title | Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study |
title_full | Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study |
title_fullStr | Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study |
title_full_unstemmed | Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study |
title_short | Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study |
title_sort | serological survey to estimate sars-cov-2 infection and antibody seroprevalence at a large public university: a cross-sectional study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401225/ https://www.ncbi.nlm.nih.gov/pubmed/37536960 http://dx.doi.org/10.1136/bmjopen-2023-072627 |
work_keys_str_mv | AT houchingwen serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT williamsstacy serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT taylorkylee serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT boyleveronica serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT bobbettbradley serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT kouvetakisjoseph serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT nguyenkeana serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT mcdonaldaaron serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT harrisvalerie serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT nusslebenjamin serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT scharfphillip serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT jehnmeganl serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT lanttimothy serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT mageemitchell serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT chungyunro serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT labaerjoshua serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy AT muruganvel serologicalsurveytoestimatesarscov2infectionandantibodyseroprevalenceatalargepublicuniversityacrosssectionalstudy |